|
gptkbp:instanceOf
|
gptkb:United_States_Supreme_Court_case
|
|
gptkbp:appealsTo
|
gptkb:United_States_Court_of_Appeals_for_the_Federal_Circuit
|
|
gptkbp:citation
|
gptkb:569_U.S._576
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:date
|
2013-06-13
|
|
gptkbp:decidedBy
|
gptkb:Supreme_Court_of_the_United_States
|
|
gptkbp:defendant
|
gptkb:Myriad_Genetics,_Inc.
|
|
gptkbp:docketNumber
|
12-398
|
|
gptkbp:fullName
|
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.
|
|
gptkbp:heldBy
|
Naturally occurring DNA sequences cannot be patented
cDNA is patent eligible because it is not naturally occurring
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AMP v. Myriad
|
|
gptkbp:legalSubject
|
gptkb:US_patent
gptkb:biotechnology
|
|
gptkbp:majorityOpinionBy
|
gptkb:Clarence_Thomas
|
|
gptkbp:originatedIn
|
gptkb:United_States_District_Court_for_the_Southern_District_of_New_York
|
|
gptkbp:plaintiff
|
gptkb:Association_for_Molecular_Pathology
|
|
gptkbp:relatedTo
|
gptkb:BRCA1_gene
gptkb:BRCA2_gene
gene patenting
|
|
gptkbp:unanimousDecision
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Association_for_Molecular_Pathology_et_al._v._Myriad_Genetics,_Inc.,_et_al.
|
|
gptkbp:bfsLayer
|
8
|